<乌鸦传媒>Another Robotic Approach for Bladder Cancer Removal Proves Its Mettle Robot-assisted laparoscopy with ICUD tied to better survival versus open surgery Apr 29, 2022
<乌鸦传媒>Program to Reduce Opioid Scripts Post-Surgery Worked for Thyroid Cancer Patients Post-surgical intervention may help to reduce the risk of opioid addiction and overdose Apr 29, 2022
<乌鸦传媒>New Guidelines Target Cancer Risk in Rare GI Syndromes Task force focuses on diagnosis, management of gastrointestinal hamartomatous polyposis syndromes Apr 28, 2022
<乌鸦传媒>When Free Flaps Fail Twice, Another Try Can Be Successful Second salvage attempt worked in 30% of cases Apr 28, 2022
<乌鸦传媒>Topical Antisepsis May Thwart SSIs in Upper Aerodigestive Tract Reconstruction Preoperative topical antisepsis mucosal preparation associated with 51% fewer infections Apr 28, 2022
<乌鸦传媒>Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency News, features, and commentary about cancer-related issues Apr 22, 2022
<乌鸦传媒>Anti-CD39 Combination Therapy Promising in Gastric/GEJ Cancer Responses in a majority of patients, evidence of durability with TTX-030, chemoimmunotherapy Apr 14, 2022
<乌鸦传媒>PARP Inhibitor-Based Triplet Promising in Endometrial Cancer Olaparib/cyclophosphamide/metformin combo appears effective in older, heavily pretreated patients Apr 11, 2022
<乌鸦传媒>New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk Apr 05, 2022
<乌鸦传媒>Black Patients More Often Get 'Substandard' Care for GI Cancers Retrospective study finds worse surgical outcomes, lower odds of receiving chemotherapy Apr 04, 2022
<乌鸦传媒>Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS Mar 25, 2022
<乌鸦传媒>Artificial Sweeteners Not So Sweet When It Comes to Cancer Risk Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
<乌鸦传媒>Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancer Should the gynecologic oncology community reconsider IP therapy? Mar 22, 2022
<乌鸦传媒>Lenvatinib Packaging for Endometrial Cancer Tied to $168 Million in Overspending Presenter breaks news at SGO that drug developer commits to overhauling dose reduction program Mar 20, 2022
<乌鸦传媒>Selinexor Proves Mettle in Advanced or Recurrent Endometrial Cancer Benefit was greatest among patients with wild-type p53 cancer in SIENDO trial Mar 20, 2022
<乌鸦传媒>Fecal Microbiome Markers Detect Pancreatic Cancer With 'High Accuracy' These markers need to be tested in a prospective cohort before clinical impact can be determined Mar 10, 2022
<乌鸦传媒>Robotic Hepatectomy Shows Benefits Over Laparoscopic Surgery Shorter hospital stay, similar perioperative outcomes in matched analysis Mar 10, 2022
<乌鸦传媒>Radioiodine for Low-Risk Thyroid Cancer: Yea or Nay? Randomized study finds no meaningful difference in events of abnormalities between groups Mar 09, 2022
<乌鸦传媒>Another Casualty of COVID-19: Evidence-Based Medicine Physician laments decline in research quality, critical appraisal during pandemic Mar 09, 2022
<乌鸦传媒>Cancer May Heighten Odds of Guillain-Barre Syndrome Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022
<乌鸦传媒>ARB-Cancer Link May Come Down to Cumulative Exposure Does a new paper resolve the conflicting safety data on the popular antihypertensives? Mar 02, 2022
<乌鸦传媒>Kids With IBD Need Close Monitoring as They Grow Up Meta-analysis confirms: substantially increased cancer risk in adulthood Mar 02, 2022
<乌鸦传媒>Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
<乌鸦传媒>AI Platform Near Perfect for Predicting Thyroid Malignancy High precision for T stage, extracapsular extension, BRAF mutation Feb 27, 2022
<乌鸦传媒>PD-L1 Inhibitor Fails to Meet PFS Target in Advanced Penile Cancer Atezolizumab did show some activity, with a 30% overall response rate Feb 22, 2022
<乌鸦传媒>Enfortumab Vedotin Promising in Neovadjuvant Therapy in Advanced Bladder Cancer Early-phase study offers 36% pCR in cisplatin-ineligible patients with muscle-invasive disease Feb 19, 2022
<乌鸦传媒>Ablating High-Grade Anal Lesions Thwarts Progression to Cancer Screening followed by aggressive therapy shows benefit in phase III ANCHOR study Feb 17, 2022
<乌鸦传媒>Sotorasib Impresses in Advanced Pancreatic Cancer ORR of 21% in heavily pretreated patients with a KRAS G12C mutation Feb 16, 2022
<乌鸦传媒>Women More Likely to Experience Severe Toxicity of Cancer Treatments Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
<乌鸦传媒>Pembrolizumab Shows Promise in Advanced Anal Cancer PD-1 inhibitor may be an option for those who have no options Feb 11, 2022
<乌鸦传媒>Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancer Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
<乌鸦传媒>Genetic Role of Alcohol-Cancer Link Strengthened In study from China, two common variants associated with lower risk of cancer in men Feb 01, 2022
<乌鸦传媒>When Strangers Deliver Bad News to Patients All too often, I end up giving prognoses to patients I barely know Jan 31, 2022
<乌鸦传媒>An 'Intriguing Failure' in Advanced, Pre-Treated GIST Second-line ripretinib unable to best sunitinib, but still had meaningful clinical activity Jan 26, 2022
<乌鸦传媒>Trial Data Confirm Heightened Risks With JAK Inhibitor May help patients and clinicians better weigh benefit against adverse effects Jan 26, 2022
<乌鸦传媒>Paclitaxel-Carboplatin Established as Standard of Care for Uterine Carcinosarcoma Median OS and PFS improved versus paclitaxel-ifosfamide Jan 25, 2022
<乌鸦传媒>GICS Roundup: PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer Jan 24, 2022
<乌鸦传媒>Adagrasib Promising in KRAS-Mutant GI Cancers The KRAS G12C inhibitor showed a disease control rate of 100% in small study Jan 24, 2022
<乌鸦传媒>Survival Bump in Biliary Cancer With Immunotherapy Plus Chemotherapy Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade Jan 23, 2022
<乌鸦传媒>Potential New First-Line Options for Unresectable Hepatocellular Carcinoma Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib Jan 22, 2022
